BACE1 and Alzheimer disease: As discussed by Ma and colleagues, these data stress the requirement for thorough preclinical studies of experimental BACE1 inhibitors, not only in animal models of AD, but also in wild type animals to evaluate their effect on normal cognitive functioning [68].